Publication details
Doporučený postup diagnostiky a léčby infekce virem hepatitidy B : Datum vydání doporučení: září 2017
| Title in English | Diagnosis and therapy of hepatitis B virus infection : Czech national guidelines. Date of release: September 2017 |
|---|---|
| Authors | |
| Year of publication | 2017 |
| Type | Article in Periodical |
| Magazine / Source | Klinická mikrobiologie a infekční lékařství |
| MU Faculty or unit | |
| Citation | |
| Keywords | chronic hepatitis B; entecavir (ETV); tenofovir disoproxil fumarate (TDF); tenofovir alafenamide (TAF); pegylated interferon alfa |
| Description | The new recommendations reflect the increase in knowledge that has been reported since the release of previous Czech guidelines in September 2014. The basis for these guidelines were the European Association for ihe Study of the Liver guidelines from April 2017. According to qualified estimates, there are 240 million people with chronic hepatitis B (HBV) infection worldwide. The Czech Republic is among the countries with a low prevalence of HBV infection. According to the latest scroprevalence study, 0.56 % of the Czech citizens were chronically infected with HBV in 2001. A similar study conducted in only two regions of the Czech Republic, in 2013 showed a prevalence of only 0.064 %. HBV infection can lead to serious life-threatening liver damage - fulminant hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC). |